Case report: Moderate therapeutic response to Bevacizumab in late-onset Labrune syndrome

Case report: Moderate therapeutic response to Bevacizumab in late-onset Labrune syndrome

Labrune syndrome (LS) is caused by SNORD118 gene mutations with a particular neuroimaging of white matter disease, intracranial calcification, and cysts. There was no effective treatment until now. An 18-year-old man with infancy-onset LS was first treated with vascular endothelial growth factor (VE...

Full description

Bibliographic Details
Main Authors: Meiping Wang, Jinmei Lu, Xiaoxi Wang, Xiaoqun Ba, Dengchang Wu, Jianfang Zhang, Jiajia Zhou, Kang Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Neurology
Subjects:
Labrune syndrome
treatment
Bevacizumab
epilepsy
late-onset
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2022.968403/full

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2022.968403/full

Similar Items